mRNA COVID-19 Vaccine
- Generic Name
- mRNA COVID-19 Vaccine
Safety Study About the mRNA Vaccines Against COVID-19 in Children (PEDIVACOV-HCSC)
- First Posted Date
- 2024-10-17
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Ana Belen Rivas Paterna
- Target Recruit Count
- 2100
- Registration Number
- NCT06646744
- Locations
- 🇪🇸
Fundacion para Investigación Biomedica Hospital Clinico San Carlos, Madrid, Spain
Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study
- Conditions
- SafetyAdverse Event Following ImmunizationBirth Outcomes
- Interventions
- Biological: IIV4 (quadrivalent inactivated influenza vaccine)
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Duke University
- Target Recruit Count
- 350
- Registration Number
- NCT06503900
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Centers for Disease Control and Prevention, Atlanta, Georgia, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children
- Conditions
- Fever After VaccinationFeverSeizures Fever
- Interventions
- Biological: Routine Childhood Vaccinations
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Duke University
- Target Recruit Count
- 600
- Registration Number
- NCT06038617
- Locations
- 🇺🇸
Kaiser Permanente Northern California, Oakland, California, United States
🇺🇸Centers for Disease Control and Prevention, Atlanta, Georgia, United States
🇺🇸Columbia University, New York, New York, United States
A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia
- Conditions
- Chronic Lymphocytic LeukemiaCOVID-19 Infection
- Interventions
- Procedure: Biospecimen CollectionBiological: Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
- First Posted Date
- 2023-01-05
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 80
- Registration Number
- NCT05672355
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
- Conditions
- Relapsing Multiple Sclerosis (RMS)
- Interventions
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT04878211
- Locations
- 🇺🇸
Dragonfly Research LLC, Wellesley, Massachusetts, United States
🇺🇸Minnesota Center Multiple Sclerosis, Plymouth, Minnesota, United States
🇺🇸The MS Center for Innovation in Care, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.